| Literature DB >> 30781607 |
Abrar F Alhameed1,2, Sara Al Khansa3,4, Hani Hasan5,6, Sherine Ismail7,8, Mohammed Aseeri9,10.
Abstract
Many hospitals face barriers in the implementation of TDM services, this study aimed to evaluate a pharmacist-led TDM service to optimize patients' outcomes. Adult patients who were administered vancomycin, gentamicin, or amikacin were included. The pre-phase included a retrospective assessment of patients and the intervention phase consisted of an educational program. The post-phase assessed patients based on TDM services provided by inpatient pharmacists on a 24-h, 7-day basis for 3 months. The primary outcome was to assess the mean difference in proportion of correct initial doses of prescribing orders. Secondary outcomes included assessing the mean differences in proportions of correct dose adjustments and correct drug sampling time. Seventy-five patients in each phase were eligible. Patients who received optimal initial dosing in the post-phase showed a higher statistical significance, mean difference of 0.31, [95% CI (0.181⁻0.4438), p < 0.0001]. Patients in the post-phase received more optimal dose adjustments, mean difference of 0.1, [95% CI (-0.560⁻0.260), p = 0.2113]. Drug levels were ordered more correctly in the post-phase, mean difference of 0.03, [95% CI (-0.129⁻0.189), p = 0.7110]. This study demonstrated the important role of TDM services led by pharmacists in optimizing the initial dosing for these antibiotics.Entities:
Keywords: TDM; aminoglycosides; drug monitoring; inpatient; pharmacist; vancomycin
Year: 2019 PMID: 30781607 PMCID: PMC6473576 DOI: 10.3390/pharmacy7010020
Source DB: PubMed Journal: Pharmacy (Basel) ISSN: 2226-4787
Figure 1Patient’s enrollment.
Baseline characteristics.
| Pre-Phase (n = 75) | Post-Phase (n = 75) | ||
|---|---|---|---|
| n (%) or Median; IQR | |||
| Age (years) | 66 (49–79) | 63 (51–77) | 0.7607 |
| Sex (male) | 38 (51%) | 38 (51%) | 1 |
| Body Mass Index (kg/m2) | 24.8 (20.6–30.8) | 25.3 (21–31.2) | 0.3904 |
| Patients on dialysis | 7 (9.33%) | 13 (17.33%) | 0.150 |
| Prescribed antibiotic | |||
| Vancomycin | 71/75 (95%) | 71/75 (95%) | 1 |
| Gentamicin | 4/75 (5%) | 3/75 (4%) | 1 |
| Amikacin | 0/75 (0%) | 1/75 (1.3%) | 1 |
| Baseline lab values at the time of initiation of antibiotic | |||
| CrCl (mL/min) b | 67.9 (37.3–106.5) | 60 (30–94) | 0.3082 |
| WBCs (×109 cells/L) | 10.9 (7.6–16.1) | 11 (7.7–16) | 0.7042 |
| Wards at which antibiotics were initiated | |||
| Emergency | 36 (48%) | 35 (46.6%) | 0.87 |
| Medical | 23 (30.7%) | 32 (42.6%) | 0.127 |
| Surgical | 16 (21.3%) | 8 (10.6%) | 0.075 |
| Indications | |||
| Skin and Soft Tissue | 5 (6.6%) | 5 (6.6%) | 1 |
| Bacteremia | 24 (32%) | 35 (46.6%) | 0.066 |
| Osteomyelitis | 6 (8%) | 3 (4%) | 0.494 |
| Pneumonia | 20 (26.6%) | 16 (21.3%) | 0.472 |
| Endocarditis | 0 (0%) | 1 (1.3%) | 1 |
| Meningitis | 8 (10.6%) | 4 (5.3%) | 0.367 |
| Urinary Tract Infection | 8 (10.6%) | 7 (9.3%) | 0.785 |
| Intra-abdominal infection | 1 (1.3%) | 4 (5.3%) | 0.367 |
| Other c | 3 (4%) | 0 (0%) | 0.367 |
Abbreviations: SrCr: serum creatinine; CrCl: creatinine clearance; WBC: white blood cells; IQR: Interquartile range, kg/m2: kilogram/meter2, cells/L: cells per liter; a: Mann–Whitney test for continuous variables, and Chi-square or Fisher’s exact tests for proportions as deemed necessary; b: based on the Cockcroft and Gault equation; c: endophthalmitis, rhinosinusitis, and nasal Methicillin-resistant staphylococcus aureus.
Primary and secondary outcomes.
| Outcome | Pre-Phase | Post-Phase | Mean Difference | |
|---|---|---|---|---|
| Optimal initial dosing | 60 % (45/75) | 91% (68/75) | 0.31 (0.18–0.44) | <0.0001 |
| Optimal dose adjustments | 55 % (61/111) | 65% (52/80) | 0.1 (−0.05–0.26) | 0.2113 |
| Optimal drug level requests | 55 % (153/279) | 58% (171/293) | 0.03 (−0.13–0.19) | 0.7110 |
Figure 2The proportion of subtherapeutic and supratherapeutic initial doses and dose adjustments in both phases.
Figure 3Types of incorrect drug levels ordered.